On December 8, 2022, Shuangcheng Pharmaceuticals Europe S.r.l closed the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.61 CNY | -2.26% | -0.71% | -25.30% |
05-07 | Shuangcheng Pharma Gets FDA Nod to Market Acromegaly Drug in US | MT |
04-29 | Hainan Shuangcheng Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.30% | 324M | |
+21.63% | 44.12B | |
+22.99% | 22.71B | |
+18.22% | 15.15B | |
+12.66% | 13.61B | |
+60.18% | 13.34B | |
-8.35% | 6.84B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.92% | 5.63B |
- Stock Market
- Equities
- 002693 Stock
- News Hainan Shuangcheng Pharmaceuticals Co., Ltd.
- Shuangcheng Pharmaceuticals Europe S.r.l announced that it has received €0.05 million in funding from Hainan Shuangcheng Pharmaceuticals Co., Ltd.